Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD) announced that CEO and chairman Lishan Aklog, M.D., will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.
The event will be webcast live and a replay will be archived on the company's Investor Relations website for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – PAVM
In the Apr 9 session, PAVM declined 0.97%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Leadership & portfolio | Positive | -3.8% | Appointed new medical devices leader and relaunched device portfolio via new subsidiary. |
| Mar 30 | Earnings & financing | Positive | +13.0% | Reported 2025 results with financings, balance sheet actions, and business updates. |
| Mar 26 | Lucid earnings update | Positive | -3.9% | Lucid reported EsoGuard revenue growth, VA contract, and real-world performance data. |
| Mar 16 | PAVmed call notice | Neutral | -0.1% | Announced timing and access details for PAVmed’s Q4 and full-year 2025 call. |
| Mar 12 | Lucid call notice | Neutral | -3.2% | Announced Lucid’s Q4 and full-year 2025 business update call and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: some strategic and earnings updates led to gains, while others, including positive Lucid-related developments, saw negative follow-through, yielding more divergences than alignments.
Over the past month, PAVmed and its subsidiary Lucid Diagnostics reported several developments. On March 26 and March 30, Lucid and PAVmed issued full-year 2025 results and business updates, with PAVmed’s update yielding a 13.03% gain while Lucid’s results saw a -3.87% move. Conference-call announcements on March 12 and March 16 prompted modest to negative reactions. A portfolio relaunch and leadership appointment on April 2 coincided with a -3.81% move. Today’s fireside chat notice fits this pattern of frequent communication around strategy and visibility.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The fireside chat will be webcast live and available via the Investor Relations Section of the Lucid Diagnostics website or by clicking here. A replay of the webcast will be archived on the website for 30 days following the live event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference-302736626.html
SOURCE Lucid Diagnostics